Genomic testing has revolutionized cancer care. A single tumor profiling can now help create a more personalized treatment plan giving the patient a much better chance at getting cured than any standard chemotherapy ever could.
However, despite such significance, the genomic testing in cancer billing continues to be one of the most complex in US healthcare domain. Practices that lean on specialists in medical billing for oncology tend to notice the difference quickly.
Why Molecular Testing Claims Fail So Often
Molecular or genomic testing claims get denied for several reasons, but some of the most common ones circle around:
- Timing; which means the date of service was incorrectly mentioned.
- The test does not comply with the payer's coverage policies.
- Prior authorization for the test is missing.
Let us now discuss these challenges in detail:
The 14-Day Rule Explained
The date of specimen collection is usually considered to be the date of service when it comes to molecular testing by Medicare. The 14 day rule is a small exception to this, and it only deals with specimens that are collected from patients treated under the outpatient provision specifically.
It does not apply to inpatients instead it is more applicable for lab services that fall under the its desired same category. Technically, those tests will be bundled, irrespective of the time of the order or performance.
For an outpatient specimen, the timing looks something like this:
- If it is ordered less than 14 days after discharge, then the test stays bundled with the hospital's claim, and the lab cannot bill Medicare directly.
- If the test is ordered at least 14 days after discharge, then the date of service can shift to the day the test was performed, so the lab can bill Medicare directly, as long as the other criteria are met.
Molecular pathology tests and advanced diagnostic laboratory tests (ADLTs) get a more flexible exception. The date of service can be the day the test was performed, with no 14-day wait, when:
- The specimen was collected during a hospital outpatient encounter,
- The test was performed after the patient was discharged,
- It was medically appropriate to collect the specimen during that encounter,
- The result did not guide treatment during that encounter, and
- The test was reasonable and medically necessary.
It can be quite challenging to keep track of these details, and a small mistake changes who gets to bill. An expert billing team will likely keep a check of the care setting first and then consider the order date. This reduces the likelihood of claim oncology claim denials.
What MolDX Means for Oncology Claims
MolDX, which is a Molecular Diagnostic Services Program, is governed by Palmetto GBA and used by several Medicare Administrative Contractors across a large part of the country. It reviews molecular tests and decides which ones are reasonable and necessary, and many local coverage determinations (LCDs) come out of that work.
A few things trip up claims most often:
- For many molecular tests, MolDX wants an unique Z-Code identifier on the claim so the contractor knows exactly which test was run. Missing out on that can lead to direct claim denials,
- The patient's situation must fit the LCD. Simply put, there must be a clear link between the result and the treatment decision.
- Medicare's policy on next-generation sequencing covers certain FDA-approved or cleared tests for advanced cancer. The patient generally cannot have had the same test before.
Prior Authorization: The Step Most Practices Rush
Commercial payers mostly need prior authorization for genomic testing services, and most of them rely on external benefit managers. Now these reviews generally circle around checking:
- The diagnosis and the stage in which it was caught
- If there were any previous treatments and diagnostic tests
- Whether the result of the test has the potential to change the treatment plan
- Sometimes they will also check the request against the NCCN guidelines too
Unable to comply with these will likely increase payer scrutiny, and the chances of the request getting denied rises significantly.
How Expert Billing Services Close the Gaps
A team focused on medical billing for oncology tackles these problems before they turn into denials. Their endeavor towards ensuring successful oncology claim processing begins even before the test is prescribed. They build a workflow to ensure proper revenue cycle management starting from the eligibility verification to the denial management.
The team will first begin by checking whether the insurer covers the prescribed test. Then they identify the payer-specific requirements like if prior authorization is needed. Such preparation reduces the likelihood of claim denials.
Additionally, when they send the authorization request, they make sure the form is accurately prepared. It includes all accurate diagnosis codes, history of patient's prior test and treatment plan and so on.
The same care shows up on the claim itself:
- Billers compare discharge and collection dates and apply the 14-day rule properly.
- They confirm who should bill, so nothing is bundled by mistake.
- They check that the right codes and Z-Codes are in place, which heads off MolDX rejections and unbundling errors.
However, denials can still happen. But when one lands, experienced staff find the cause, pull the records, and appeal using the payer's own policy language. Over time, they also coach clinical staff on what belongs in the chart, such as why a result changes treatment, so the documentation holds up under review.
Few practices have the time to track every payer's genomic testing policy. Rules shift and new codes arrive each year, and one person cannot realistically follow all of it. A dedicated team does this every day, which is the whole point.
Final Thoughts
With the kind of benefits it offers, the use of genomic testing in oncology care is likely to increase with time. However, treating the claims for these services as any routine ones will only cause the practice to lose their hard-earned money.
The 14-day rule, MolDX requirements, and prior authorization all of them come with their unique challenges and oftentimes they all can pile up against one single claim. With real expertise in medical billing for oncology behind them, practices can safeguard their revenue, reduce the number of rework, and keep their attention on what matters. Simply put, practices can focus on getting patients the right test and the right treatment without delay.
